| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $8,983,487 | 4 | 100 |
| Savitz Ryan | CFO & CBO | 0 | $0 | 2 | $1.6M | $-1.6M |
| Randhawa Simrat | EVP, Head of R&D | 0 | $0 | 2 | $7.38M | $-7.38M |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Over the last 12 months, insiders at Dianthus Therapeutics, Inc. have bought $0 and sold $8.98M worth of Dianthus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Dianthus Therapeutics, Inc. have bought $0 and sold $8.98M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2025-12-04 | Sale | Savitz Ryan | CFO & CBO | 20,000 0.0558% | $45.18 | $903,600 | -2.45% | |
| 2025-11-14 | Sale | Randhawa Simrat | EVP, Head of R&D | 109,031 0.3235% | $38.14 | $4.16M | +17.73% | |
| 2025-11-13 | Sale | Randhawa Simrat | EVP, Head of R&D | 87,507 0.2506% | $36.81 | $3.22M | +15.45% | |
| 2025-09-09 | Sale | Savitz Ryan | CFO & CBO | 20,000 0.0611% | $35.00 | $700,000 | +3.98% |
| Increased Positions | 93 | +84.55% | 16M | +40.11% |
| Decreased Positions | 49 | -44.55% | 8M | -20.28% |
| New Positions | 51 | New | 6M | New |
| Sold Out Positions | 14 | Sold Out | 3M | Sold Out |
| Total Postitions | 154 | +40% | 47M | +19.83% |
| Fmr Llc | $251,543.00 | 13.89% | 5.97M | +1M | +31.39% | 2025-09-30 |
| Fairmount Funds Management Llc | $139,332.00 | 7.69% | 3.31M | +600,000 | +22.16% | 2025-09-30 |
| Avidity Partners Management Lp | $134,992.00 | 7.45% | 3.2M | +1M | +83.84% | 2025-09-30 |
| Ra Capital Management, L.P. | $120,775.00 | 6.67% | 2.87M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $108,597.00 | 6% | 2.58M | +3M | +3,366.88% | 2025-09-30 |
| Octagon Capital Advisors Lp | $101,814.00 | 5.62% | 2.42M | +75,000 | +3.2% | 2025-09-30 |
| Point72 Asset Management, L.P. | $86,028.00 | 4.75% | 2.04M | +649,443 | +46.64% | 2025-09-30 |
| Tcg Crossover Management, Llc | $70,636.00 | 3.9% | 1.68M | +175,000 | +11.65% | 2025-09-30 |
| Vanguard Group Inc | $69,186.00 | 3.82% | 1.64M | +196,117 | +13.56% | 2025-09-30 |
| Blackrock, Inc. | $56,458.00 | 3.12% | 1.34M | -18,690 | -1.38% | 2025-09-30 |